首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain.
【2h】

Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain.

机译:大鼠脑中非肾上腺素受体咪唑x生结合位点的表征和放射自显影定位。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. In rat whole brain homogenates, saturation analysis revealed that both [3H]-idazoxan and [3H]-RX821002, a selective alpha 2-adrenoceptor ligand, bound with high affinity to an apparent single population of sites. However, the Bmax for [3H]-idazoxan was significantly (P less than 0.01) greater than that for [3H]-RX821002. 2. In competition studies, (-)-adrenaline displaced 3 nM [3H]-idazoxan binding with an affinity consistent with [3H]-idazoxan labelling alpha 2-adrenoceptors. However, this displacement was incomplete since 23.68 +/- 1.11% of specific [3H]-idazoxan binding remained in the presence of an excess concentration (100 microM) of (-)-adrenaline. In contrast, unlabelled idazoxan promoted a complete displacement of [3H]-idazoxan binding with a Hill slope close to unity and an affinity comparable with its KD determined in saturation studies. 3. Displacement of [3H]-idazoxan binding by the alpha 2-adrenoceptor antagonists yohimbine, RX821002 (2-(2-methoxy-1,4-benzodioxan-2-yl)-2-imidazoline) and RX811059 (2-(2-ethoxy-1,4-benzodioxan-2-yl)-2-imidazoline) was more complex, with Hill slopes considerably less than unity, and best described by a two-site model of interaction comprising a high and low affinity component. The proportion of sites with high affinity for each antagonist was similar (60-80%). 4. The rank order of antagonist potency for the high affinity component in each displacement curve (RX821002 greater than RX811059 greater than yohimbine) is similar to that determined against the binding of [3H]-RX821002 to rat brain, suggesting that these components reflect the inhibition of [3H]-idazoxan binding to alpha 2-adrenoceptors.(ABSTRACT TRUNCATED AT 250 WORDS)
机译:1.在大鼠全脑匀浆中,饱和度分析显示[3H]-咪唑azo和[3H] -RX821002(一种选择性的α2肾上腺素受体配体)都与表观的单个位点高亲和力结合。但是,[3H]-咪唑azo的Bmax明显大于[3H] -RX821002的Bmax(P小于0.01)。 2.在竞争研究中,(-)-肾上腺素置换了3 nM [3H]-咪唑azo的结合,其亲和力与[3H]-咪唑x标记的α2-肾上腺素受体一致。但是,这种置换是不完全的,因为在过量浓度(100 microM)的(-)-肾上腺素存在的情况下,仍存在23.68 +/- 1.11%的特定[3H]-咪唑烷结合。相比之下,未标记的异唑烷酮可促进[3H]-异唑烷酮结合的完全置换,希尔斜率接近于1,亲和力可与饱和研究中确定的KD相媲美。 3.由α2-肾上腺素受体拮抗剂育亨宾,RX821002(2-(2-甲氧基-1,4-苯并二恶烷-2-基)-2-咪唑啉)和RX811059(2-(2 -乙氧基-1,4-苯并二恶烷-2-基)-2-咪唑啉)更复杂,希尔斜率大大小于1,并且最好通过包含高和低亲和力组分的两点相互作用模型来描述。对每种拮抗剂具有高亲和力的位点比例相似(60-80%)。 4.在每个位移曲线中,高亲和力组分的拮抗剂效价等级顺序(RX821002大于RX811059大于育亨宾)类似于针对[3H] -RX821002与大鼠脑的结合而确定的排序,表明这些组分反映了抑制[3H]-恶唑烷与α2-肾上腺素受体的结合。(摘要截短为250字)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号